口服选择性酪氨酸激酶2抑制剂氘可来昔替尼
A review on pharmacological and clinical studies of deucravacitinib
张恒源 1罗金雀1
作者信息
- 1. 长沙医学院药学院新型药物制剂研发湖南省重点实验室,长沙 410219
- 折叠
摘要
氘可来昔替尼(deucravacitinib)是第 1 个获批上市的新型口服选择性酪氨酸激酶 2(tyrosine kinase 2,TYK2)抑制剂,用于治疗多种自身免疫疾病,临床应用前景广泛.本文对deucravacitinib的作用机制、研发历程、临床评价、同靶点药物研究进展等进行综述.
Abstract
Deucravacitinib is the first-in-class oral selective tyrosine kinase 2(TYK2)inhibitor.It is widely investigated in clinical trials for the treatment of autoimmune and chronic inflammatory diseases.In this review,we aim to highlight the mechanism,discovery history,clinical evaluation,and research progress of drugs also targeting at TYK2.
关键词
氘可来昔替尼/选择性酪氨酸激酶2抑制剂/自身免疫及慢性炎症疾病/银屑病Key words
deucravacitinib/selective tyrosine kinase 2 inhibitor/autoimmune and chronic inflammatory diseases/psoriasis引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据